Searching for Therapeutic Drugs that Target Causative Proteins of Alport Syndrome (image) Kumamoto University Share Print E-Mail Caption Collagen IV alpha-3, alpha-4, and alpha-5 in Alport Syndrome cannot form trimers so the discovery of compounds that leads to or improves their formation will lead to the development of novel therapies. New work from Kumamoto University makes it possible to evaluate the trimerization of collagen IV alpha chains by measuring luminescence. Compounds that induce luminescence in the NanoLuc-Col4 system are likely to promote trimerization. Credit Dr. Kohei Omachi Usage Restrictions These images may only be used in conjunction with the accompanying release, or stories written about the work described in the release with reference to the original work. Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.